Table 3.
Characteristics of patients with and without recurrence in breast conserving group
| Variable | Recurrence (n=6) | No recurrence (n=121) | P |
|---|---|---|---|
| Age (yr) | 46.2±6.9 | 48.5±8.9 | .697 |
| ≤40 | 1(16.7%) | 17(14.0%) | |
| 41-60 | 5(83.3%) | 91(75.2%) | |
| ≥61 | 0 | 13(10.7%) | |
| Tumor size (mm) | 51.4±28.0 | 23.5±19.1 | .000 |
| ≤15 | 0 | 58(47.9%) | |
| 16-40 | 1(16.7%) | 42(34.7%) | |
| ≥41 | 5(83.3%) | 21(17.4%) | |
| Tumor grade | .033 | ||
| 1 | 0 | 28(23.1%) | |
| 2 | 2(33.3%) | 67(55.4%) | |
| 3 | 4(66.7%) | 26(21.5%) | |
| Margin (mm) | 10.6±8.6 | 9.4±7.6 | .314 |
| >9 | 4(66.7%) | 46(38.0%) | |
| 1-9 | 2(33.3%) | 57(47.1%) | |
| <1 | 0 | 18(14.9%) | |
| Multifocality | .201 | ||
| Yes | 2(33.3%) | 16(13.2%) | |
| No | 4(66.7%) | 105(86.8%) | |
| Receptor status | .031 | ||
| ER positive | 2(33.3%) | 94(77.7%) | |
| ER negative | 4(66.7%) | 27(22.3%) | |
| PR positive | 2(33.3%) | 83(68.6%) | .092 |
| PR negative | 4(66.7%) | 38(31.4%) | |
| C-erbB2 | .354 | ||
| 0 | 0 | 16(13.2%) | |
| 1+ | 0 | 31(25.6%) | |
| 2+ | 3(50%) | 28(23.1%) | |
| 3+ | 3(50%) | 44(36.4%) | |
| Unknown | 0 | 2(1.4%) | |
| Ki67 (%) | .700 | ||
| <10 | 2(33.3%) | 65(53.7%) | |
| 10-19 | 2(33.3%) | 22(18.2%) | |
| ≥20 | 2(33.3%) | 31(25.6%) | |
| VNPI score | .260 | ||
| 4-6 | 0 | 38(31.4%) | |
| 7-9 | 5(83.3%) | 70(57.9%) | |
| 10-12 | 1(16.7%) | 13(10.7%) | |
| Tamoxifen | 2(33.3%) | 93(76.9%) | .035 |
| Radiation | 6(100.0%) | 89(73.6%) | .336 |